Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Medicare is expanding its drug price negotiation program to include 15 more medications, including popular drugs like Ozempic ...

Ozempic, the blockbuster diabetes treatment from Novo Nordisk, could be next in line to face price negotiations between manufacturers and Medicare. The Biden administration released the first 10 ...

Medicare covers Ozempic for Type 2 diabetes Medicare prescription drug plans might cover Ozempic, but only to treat diabetes. In 2021, Medicare spent over $2.6 billion to cover Ozempic prescriptions.

A better way According to CMS, close to 2.3 million seniors enrolled in Medicare are using Novo Nordisk’s semaglutide medications branded as Ozempic, Wegovy and Rybelsus.

Medicare Part D spent a total of $4.6 billion on Ozempic in 2022, based on the most recent data we have from the Centers for Medicare & Medicaid Services. This spending covered 780,253 ...

Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

Together, those 25 drugs account for a third of Medicare spending on prescriptions, Becerra said. Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.